Prospective Assessment of Liver Function by an Enzymatic Liver Function Test to Estimate Short-Term Survival in Patients with Liver Cirrhosis
- 66 Downloads
MELD attempts to objectively predict the risk of mortality of patients with liver cirrhosis and is commonly used to prioritize organ allocation. Despite the usefulness of the MELD, updated metrics could further improve the accuracy of estimates of survival.
To assess and compare the prognostic ability of an enzymatic 13C-based liver function test (LiMAx) and distinct markers of liver function to predict 3-month mortality of patients with chronic liver failure.
We prospectively investigated liver function of 268 chronic liver failure patients without hepatocellular carcinoma. Primary study endpoint was liver-related death within 3 months of follow-up. Prognostic values were calculated using Cox proportional hazards and logistic regression analysis.
The Cox proportional hazard model indicated that LiMAx (p < 0.001) and serum creatinine values (p < 0.001) were the significant parameters independently associated with the risk of liver failure-related death. Logistic regression analysis revealed LiMAx and serum creatinine to be independent predictors of mortality. Areas under the receiver-operating characteristic curves for MELD (0.86 [0.80–0.92]) and for a combined score of LiMAx and serum creatinine (0.83 [0.76–0.90]) were comparable.
Apart from serum creatinine levels, enzymatic liver function measured by LiMAx was found to be an independent predictor of short-term mortality risk in patients with liver cirrhosis. A risk score combining both determinants allows reliable prediction of short-term prognosis considering actual organ function.
Trial Registration Number (German Clinical Trials Register) # DRKS00000614.
KeywordsEnd-stage liver disease Liver function test LiMAx MELD Risk assessment Survival
Area under the receiver-operating characteristics
End-stage liver disease
Hepatitis C virus
Intraclass correlation coefficient
International normalized ratio
Maximum liver function capacity
Model for end-stage liver disease
Nonalcoholic fatty liver disease
Spontaneous bacterial peritonitis
United Kingdom Model for End-Stage Liver Disease
We gratefully thank Ms. Antonia Rothkäppel for the performance of LiMAx measurements. Further, we want to thank Alexander Krannich and Prof. Dr. rer. nat. habil. Klaus-Dieter Wernecke for performing statistical analyses. We also want to thank Mr. Jim Orr and Mr. Andrzej Juraszek for editing the final manuscript.
This study was part of the d-LIVER project and was funded in part by a Grant from the European Commission’s Seventh Framework Programme/European Research Council, grant agreement number 287596.
Compliance with ethical standards
Conflict of interest
Martin Stockmann is the inventor of the LiMAx test and has capital interest in Humedics, the company marketing the LiMAx test. Maximilian Jara and James Orr disclose having received research Grants in order of the d-LIVER European Commission’s Seventh Framework Programme/European Research Council, Grant Agreement Number 287596—www.d-liver.eu. Martin Stockmann was also steering committee member for the d-LIVER project. Remaining authors who have taken part in this study declared no conflict of interest with respect to this manuscript.
- 30.Salerno F, Borroni G, Moser P, Sangiovanni A, et al. Prognostic value of the galactose test in predicting survival of patients with cirrhosis evaluated for liver transplantation. A prospective multicenter Italian study. AISF Group for the Study of Liver Transplantation. Associazione Italiana per lo Studio del Fegato. J Hepatol. 1996;25:474–480.CrossRefGoogle Scholar